Navicare Biotech Co., Ltd. (TPEX:8472)
Taiwan · Delayed Price · Currency is TWD 74.20
-4.00 (-5.12%)
Sep 8, 2026, 1:30 PM CST
Navicare Biotech Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,321 | 1,265 | 461 | 670 | 745 | 896 | |
Market Cap Growth | -8.14% | 174.23% | -31.13% | -10.12% | -16.83% | -24.85% |
Enterprise Value | 1,475 | 1,430 | 629 | 754 | 680 | 231 |
Last Close Price | 74.50 | 71.30 | 26.00 | 37.75 | 42.00 | 48.76 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 83.14 |
Forward PE | - | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 |
PS Ratio | 2.61 | 2.65 | 1.37 | 1.72 | 2.25 | 2.93 |
PB Ratio | 5.10 | 4.68 | 1.62 | 1.84 | 1.79 | 1.70 |
P/TBV Ratio | 5.19 | 4.76 | 1.65 | 1.87 | 1.82 | 1.73 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.92 | 2.99 | 1.87 | 1.94 | 2.05 | 0.76 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.23 | 1.21 | 0.92 | 0.68 | 0.56 | 0.03 |
Net Debt / Equity Ratio | 0.59 | 0.36 | 0.57 | 0.30 | -0.03 | -1.22 |
Net Debt / EBITDA Ratio | -15.43 | -4.63 | -2.43 | -1.31 | 0.17 | 53.24 |
Net Debt / FCF Ratio | -8.48 | -29.68 | -2.26 | -0.75 | 0.02 | 9.36 |
Asset Turnover | 0.50 | 0.47 | 0.31 | 0.33 | 0.29 | 0.28 |
Inventory Turnover | 8.76 | 6.68 | 3.27 | 4.81 | 5.62 | - |
Quick Ratio | 0.52 | 0.56 | 0.24 | 0.40 | 0.46 | 1.38 |
Current Ratio | 0.64 | 0.68 | 0.42 | 0.59 | 0.72 | 1.59 |
Return on Equity (ROE) | -4.32% | -8.38% | -24.19% | -13.31% | -18.10% | 1.96% |
Return on Assets (ROA) | -1.23% | -1.94% | -4.47% | -4.71% | -3.64% | -0.78% |
Return on Invested Capital (ROIC) | -4.99% | -7.81% | -16.99% | -20.58% | -45.91% | - |
Return on Capital Employed (ROCE) | -4.10% | -6.30% | -17.60% | -16.90% | -11.10% | -2.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.86% | -1.84% | -17.02% | -7.74% | -11.10% | 1.20% |
FCF Yield | -1.37% | -0.26% | -15.49% | -21.55% | -63.50% | -7.69% |
Dividend Yield | - | - | - | - | - | 3.08% |
Payout Ratio | - | - | - | - | - | 411.58% |
Buyback Yield / Dilution | - | - | - | - | 0.15% | 1.45% |
Total Shareholder Return | - | - | - | - | 0.15% | 4.53% |